AI assistant
Immunovant, Inc. — Director's Dealing 2022
Jan 12, 2022
31436_dirs_2022-01-12_b2963db4-a0c4-4b7b-8001-dc544c731ec8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2022-01-10
Reporting Person: Pande Atul (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-10 | Common Stock | A | 21726 | — | Acquired | 61926 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-10 | Stock Option (right to buy) | $7.94 | A | 71492 | Acquired | 2032-01-10 | Common Stock (71492.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5000 | Indirect |
Footnotes
F1: Represents the number of shares underlying restricted stock units awards ("RSUs").
F2: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3: These shares are owned by a trust (the "Trust"). Certain members of the Reporting Person's immediate family are beneficiaries of the Trust.
F4: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.